Recent Episodes

Bladder-sparing options for BCG-unresponsive non-muscle invasive bladder cancer have transformed since 2020, according to Saum Ghodoussipour, MD.

The FDA’s decision on iberdomide is a “landmark approval” for those with multiple myeloma, according to Surbhi Sidana, MD.

Experts highlight the origins and significance of World Radiotherapy Awareness Day and discuss global access challenges surrounding modern radiation oncology.

Experts discussed the rapidly expanding radiopharmaceutical paradigm and how to integrate such technology into real-world oncology practice.

Experts highlight how AI-based tools can assist with digital pathology, documentation, medical imaging, and other relevant areas in genitourinary oncology.

Two pharmacy specialists discuss real-world data and clinical trial findings on the use of CAR T-cell therapy for pediatric patients with hematologic cancers.

The approval of Orca-T represents a “big advance” that must be studied further, according to Wendy Stock, MD.

Experts discuss sequencing HER2-, FGFR3-, and nectin-4–directed therapies after enfortumab vedotin and pembrolizumab in urothelial cancer.

Experts discuss how to navigate coding, reimbursement, and other potential financial strains when treating patients via radiotherapy.

Experts highlight how updates on the EV-302 and RAMPART studies may influence care across different bladder and kidney cancer populations.

The latest conversation in RadOnc on the Run explores patient and provider considerations for navigating cancer diagnosis, treatment, and recovery.

Chinmay Jani, MD, discussed work he presented at the 2026 ASCO Meeting and future directions for precision medicine and clinical trials in lung cancer care.

Experts discuss how updated findings from the TALAPRO-3 and PROTEUS trials may affect the prostate cancer paradigm.

Experts discuss abstracts from the 2026 ASCO Annual Meeting that may represent critical advances across multiple myeloma, leukemia, and lymphoma.

Nathan Goodyear, MD, discussed how prescribing exercise may enhance the efficacy of standard oncologic regimens for patients with cancer.

Host Brandon Mancini, MD, MBA, FACRO, discusses stereotactic radiosurgery, proton therapy, and other relevant modalities in the management of brain tumors.

Mitchell E. Horwitz, MD, discussed how omidubicel and other advances in allogeneic transplantation have affected different hematologic oncology populations.

Experts discuss how checkpoint inhibitors, cystectomy, and other treatment modalities fit into the current landscape for non–muscle-invasive bladder cancer.

Experts outline technological advances, treatment de-escalation strategies, and lifestyle factors that may affect treatment for head and neck cancers.

Experts discussed a case study involving a patient with multiple myeloma who developed CAR T-cell–related lymphomagenesis in the gastrointestinal tract.

Experts discuss the “transformational” potential of enfortumab vedotin plus pembrolizumab for patients with muscle-invasive bladder cancer.

Young patients with breast cancer should always aim to advocate for themselves, said Shari Goldfarb, MD.

Experts discussed the critical intersection of oncology and mental health, which included identifying and mitigating suicide risk factors.

Experts discuss the evolution of rectal cancer care from the use of “cookie cutter” approaches to the growth of personalized treatment pathways.

Julian Hong, MD, MS, offered strategies for providing mental health services to routine workflows for patients undergoing anticancer treatment.

Experts detail presentations that may influence the standard of care across different bladder, kidney, and prostate cancer populations.

Looking ahead, local therapies and biomarkers may become even more important in the management of kidney cancer.

Experts explore the complexities of cannabis use, the financial impact, and best practices for administration in patients with cancer.